协变量自适应随机化生存试验的样本量评估与期中分析策略
本研究探讨协变量自适应随机化下基于生存结局的样本量估算与期中分析策略,通过模拟评估简单随机化、分层置换区组随机化和协变量自适应偏币随机化下的检验性能,提出期中分析的有效假设检验方法并重新估算样本量,以RE01试验和一项肺癌研究作为预试验验证策略有效性。
要点
- 协变量自适应随机化下生存试验的样本量需重新评估,简单随机化、分层置换区组随机化和协变量自适应偏币随机化的检验性能通过模拟评估。
- 期中分析中因期中监测前后数据相关,多次检验可能膨胀整体I类错误率,需采用有效的假设检验方法。
- 提出的样本量公式和期中分析策略经综合模拟及敏感性分析评估,并在RE01试验和肺癌研究中验证其有效性。
核心结论
- 提出的样本量估算公式和期中分析策略在协变量自适应随机化下是有效的。
研究设计与样本
- 通过综合模拟评估所提出公式和期中策略的性能,包括敏感性分析,并以RE01试验和一项肺癌研究作为预试验。
主要发现
- 在简单随机化、分层置换区组随机化和协变量自适应偏币随机化下评估了基于计算样本量的检验性能。
- 期中分析中因期中监测前后数据相关,多次检验可能膨胀整体I类错误率,提出了有效的假设检验方法并重新估算样本量。
- 模拟和预试验显示所提出的策略在协变量自适应随机化下有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Estimating the required sample size is an essential task for a clinical trial. It ensures statistical power and makes it possible to draw meaningful conclusions from the study results. Moreover, to minimize treatment imbalances within each covariate subgroup, covariate-adaptive randomization is a popular method. The first aim of this study is to investigate the required sample size for covariate-adaptive randomization based on survival outcomes. We evaluate the testing performance using the calculated sample size under simple randomization, stratified permuted block randomization, and covariate-adaptive biased coin randomization. To provide preliminary insights into the trial's progress and potential efficacy, an interim analysis is commonly conducted. The second aim of the study is to provide a strategy for interim analysis in covariate-adaptive randomization trials, which involves stopping the trial early based on accumulating data if one treatment arm proves to be significantly more effective or harmful than the others. Because the data collected before and after the interim monitoring time are dependent, performing multiple tests may inflate the overall Type I error rate. We thus re-estimate the required sample size, propose a valid hypothesis testing method for interim analysis, and study the underlying theoretical properties of the testing statistics, incorporating covariate-adaptive randomization. The performance of the proposed formula and interim strategy is evaluated through comprehensive simulations, including a sensitivity analysis. We also provide the R code to benefit the readers. Finally, two survival trials, the RE01 trial and a lung cancer study, are treated as pilot studies, and we show that the proposed strategies are valid under covariate-adaptive randomization.
引用
- Su PF, Wu CC. Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate-Adaptive Randomization. Stat Med. 2025. PMID: 40481756. doi:10.1002/sim.70149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。